Hot Pursuit     02-Mar-23
Zydus Life gets final USFDA nod for Acyclovir cream
The drug maker has received final approval from US Food and Drug Administration (USFDA) for Acyclovir Cream.
The said drug is equivalent to reference listed drug, Zovirax Cream.

Acyclovir belongs to a class of medications known as antivirals. Acyclovir cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips.

The product will be launched shortly in the US market. It will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad, India.

Acyclovir Cream had annual sales of $16.9 million in the United States (IQVIA MAT Dec. 2022).

As on 31 December 2022, the group now has 348 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is engaged in an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes active pharmaceutical ingredients [API] and human formulations.

The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.

The scrip declined 1.12% to Rs 466.85 on the BSE.

Previous News
  Zydus Board approves business transfer agreement for acquisition of API biz of Sterling Biotech
 ( Corporate News - 17-Sep-24   12:04 )
  Zydus enters into licensing and supply agreement with MSN Laboaratories
 ( Corporate News - 17-May-24   09:07 )
  Sensex gains 239 pts; metal shares shine; VIX rallies 3.35%
 ( Market Commentary - Mid-Session 31-Jul-24   12:33 )
  Zydus Life gains as Q1 PAT climbs 31% YoY to Rs 1,420 cr
 ( Hot Pursuit - 09-Aug-24   15:38 )
  Zydus Lifesciences consolidated net profit rises 53.24% in the September 2023 quarter
 ( Results - Announcements 07-Nov-23   12:50 )
  Zydus receives USFDA tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets
 ( Corporate News - 14-Jun-24   13:42 )
  Zydus announces NDA acceptance of Desidustat in China by NMPA
 ( Corporate News - 23-Apr-24   16:06 )
  Zydus Life rises on USFDA nod for dyskinesia treatment drug
 ( Hot Pursuit - 28-Aug-24   09:57 )
  Board of Zydus Lifesciences approves buyback of Rs 600 cr
 ( Corporate News - 09-Feb-24   17:50 )
  Zydus receives Mexican regulatory approval for breast cancer drug
 ( Corporate News - 31-Jul-24   14:00 )
  Zydus Lifes rises after receiving approval from COFEPRIS for Trastuzumab biosimilar
 ( Hot Pursuit - 31-Jul-24   12:09 )
Other Stories
  Tata Motors total sales drop 11% YoY in Sept’24
  01-Oct-24   15:33
  Vipul Organics hits all-time high after board OKs Rs 25 cr right issue
  01-Oct-24   15:06
  Magellanic Cloud Ltd leads losers in 'A' group
  01-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  01-Oct-24   14:45
  GE Power India rises on bagging order worth Rs 240-cr
  01-Oct-24   14:41
  Volumes jump at Caplin Point Laboratories Ltd counter
  01-Oct-24   14:30
  TVS Motor registers 20% growth in September 2024 sales; Q2 total sales at 12.28 lakh units
  01-Oct-24   14:07
  Oil and Gas shares slide
  01-Oct-24   14:00
  Telecom shares fall
  01-Oct-24   14:00
  Real Estate stocks slide
  01-Oct-24   14:00
Back Top